Checkpoint Therapeutics Files 8-K on Financials
| Field | Detail |
|---|---|
| Company | Checkpoint Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Mar 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Checkpoint Therapeutics dropped an 8-K on March 28th detailing their financial condition. Check it out.
AI Summary
Checkpoint Therapeutics, Inc. filed an 8-K on March 28, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing provides investors with an update on Checkpoint Therapeutics' financial health and operational results, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Checkpoint Therapeutics, Inc. (company) — Registrant
- March 28, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- Waltham, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Checkpoint Therapeutics, Inc., and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 28, 2025.
Where is Checkpoint Therapeutics, Inc. headquartered?
Checkpoint Therapeutics, Inc. is headquartered at 95 Sawyer Road, Suite 110, Waltham, MA 02453.
In which state was Checkpoint Therapeutics, Inc. incorporated?
Checkpoint Therapeutics, Inc. was incorporated in Delaware.
What is the Commission File Number for Checkpoint Therapeutics, Inc.?
The Commission File Number for Checkpoint Therapeutics, Inc. is 001-38128.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding Checkpoint Therapeutics, Inc..